Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform ...

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are ...

Dish,” to test anti-amyloid therapies. The approach has already been used to screen thousands of compounds and enables more ...

Caris Life Sciences® , a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris?led study in The Oncologist ...

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and ...

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited – ...

Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today announced that the independent Safety Review Committee (SRC) has completed its review of safety data from Cohort ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026 ...

A biotechnology spin-off from northern Greece is attracting investment interest from Switzerland, the United States and ...

Healthtech and edtech are two of the fastest growing sectors, with the healthtech market size to reach $3.1 billion by 2033, ...